Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
CIOMS FORM DE-BFARM-16070581 SUSPECT ADVERSE REACTION REPORT I. REACTION INFORMATION 1. PATIENT INITIALS 1a. COUNTRY DE privacy 2. DATE OF BIRTH DA MO YR 2a. AGE 33 (Year) 3. SEX Female 4-6 REACTION ONSET DA MO YR 19 07 2014 8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION ¨ PATIENT DIED 7. + 13. DESCRIBE REACTION(S) (including relevant tests/lab data) Beidseitige Lungenembolie [ MedDRA 18.1 LLT (10037377): Pulmonary embolism ] kurzzeitiger Herzstillstand [ MedDRA 18.1 LLT (10007515): Cardiac arrest ] [ MedDRA 18.1 LLT (10004982): Blackout ] Case narrative including clinical course, therapeutic measures, outcome and additional relevant information: Nach 6 Monaten Antibabypille beidseitige Lungenembolie mit Bewusstlosigkeit und kurzzeitigem Herzstillstand. Behandlung mit Spritzen und Marcumar auf der Intensivstation. Keine Gerinnungskrankheiten diagnostiziert. þ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION ¨ INVOLVED PERSISTENCE OR SIGNIFICANT DISABILITY OR INCAPACITY þ LIFE THREATENING ¨ CONGENITAL ANOMALY / BIRTH DEFECT þ OTHER MEDICALLY IMPORTANT CONDITION II. SUSPECT DRUG(S) INFORMATION (cont.) 20. DID REACTION ABATE 14. SUSPECT DRUG(S) (include generic name) AFTER STOPPING DRUG? Maxim 15. DAILY DOSE(S) 16. ROUTE(S) OF ADMINISTRATION "täglich" Oral 17. INDICATION(S) FOR USE ¨ YES ¨ NO ¨ NA 21. DID REACTION REAPPEAR AFTER REINTRODUCTION? ¨ YES ¨ NO ¨ NA Bleeding menstrual heavy 18. THERAPY DATES (from/to) 19. THERAPY DURATION from 15-JAN-2014 6 Month III. CONCOMITANT DRUG(S) AND HISTORY 22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergics, pregnancy with last month of period, etc.) IV. SENDER INFORMATION 24a. NAME AND ADRESS OF SENDER BfArM Pharmakovigilanz Kurt-Georg-Kiesinger-Allee 3 53175 Bonn, DE 24b. MFR CONTROL NO. DE-BFARM-16070581 24c. DATE RECEIVED BY MANUFACTURER 03-MAR-2016 DATE OF THIS REPORT 03-MAR-2016 24d. REPORT SOURCE ¨ STUDY ¨ LITERATURE ¨ HEALTH PROFESSIONAL 25a. REPORT TYPE þ INITIAL ¨FOLLOW UP ¨ FINAL (Cont.) = Continuation on attached sheet(s) BfArM Pharmakovigilanz Kurt-Georg-Kiesinger-Allee 3 53175 Bonn, DE Continuation sheet for CIOMS report DE-BFARM-16070581 7. + 13. Describe Reaction(s) (including relevant tests/lab data) Reaction text as reported MedDRA coding Duration Beidseitige Lungenembolie [MedDRA 18.1 PT (10037377): Pulmonary embolism ] Report Date: 03-MAR-2016 Report Page: 2 of 4 (... continuation ...) Outcome* Term highlighted Time interval 1** Time interval 2*** Start date Unknown 6 Month 19-JUL-2014 Unknown 6 Month 19-JUL-2014 Unknown 6 Month 19-JUL-2014 End date [ MedDRA 18.1 LLT (10037377): Pulmonary embolism ] kurzzeitiger Herzstillstand [MedDRA 18.1 PT (10007515): Cardiac arrest ] [ MedDRA 18.1 LLT (10007515): Cardiac arrest ] [MedDRA 18.1 PT (10024855): Loss of consciousness ] [ MedDRA 18.1 LLT (10004982): Blackout ] * Outcome of reaction/event at the time of last observation ** Time interval between beginning of suspect drug administration and start of reaction/event *** Time interval between last dose and start of reaction/event Results of tests Date Test Result 14. Suspect Drug(s) (including generic name) Suspect Drug and batch no. Start date Maxim 15-JAN2014 End date Name of holder/applicant Authorization/Application Number Country of authorization/application Pharmaceutical form (Dosage form) Parent route of administration (in case of a parent child/fetus report) Gestation period at time of exposure Time interval between beginning of drug administration and start of reaction/event Action(s) taken with drug Additional information on drug Normal low range Normal high range More inform. available (... continuation ...) Identification of the country where the drug was obtained Time interval between last dose of drug and start of reaction/event Unit Duration Dose * Route(s) of Administration Indication(s) 6 Month A: täglich B: C: D: E: Oral Bleeding menstrual heavy BfArM Pharmakovigilanz Kurt-Georg-Kiesinger-Allee 3 53175 Bonn, DE Continuation sheet for CIOMS report DE-BFARM-16070581 Report Date: 03-MAR-2016 Report Page: 3 of 4 Did reaction reappear after reintroduction? * A: Dosage Text B: Cumulative dose number (to first reaction) C: Structure dosages number D: Number of separate dosages E: Number of units in the interval Active drug substance name ethinylestradiol dienogest Report duplicates Duplicate source Duplicate number Paul-Ehrlich-Institut DE-CADRBFARM-2016011781 Parent Parent identification Date of birth Age LMP date Weight(kg) Height(cm) Sex Text for relevant medical history and concurrent conditions 0 ADMINISTRATIVE AND IDENTIFICATION INFORMATION Safetyreportversion 1 Identification of the country where the reaction/event occur Deutschland Serious Yes Date Format of receipt of the most recent information for this report 20160303 Additional documents No List of documents held by sender Does this case fulfill the local criteria for an expedited report? Yes Regulatory authority's case report number DE-CADRBFARM-2016011781 Other case identifiers in previous transmissions Yes Was the case medically confirmed, if not initially from health professional? No Primary source(s) of information Study name Reporter postcode Reporter country Qualification 71 Consumer or other non health professional Deutschland Literature reference(s) SENDER INFORMATION (... continuation ...) Type Regulatory Authority Organisation BfArM Sponsor study number Study type in which the reaction(s)/event(s) were observed BfArM Pharmakovigilanz Kurt-Georg-Kiesinger-Allee 3 53175 Bonn, DE Continuation sheet for CIOMS report DE-BFARM-16070581 Department Pharmakovigilanz Street address Kurt-Georg-Kiesinger-Allee 3 City Bonn Postcode 53175 Country Deutschland Fax Telephone E-mail address [email protected] PATIENT INFORMATION (... continuation ...) Investigation number Gestation period Patient age group Adult Weight (kg) 85 Height (cm) 163 Last menstrual periode date Text for relevant medical history and concurrent conditions >18.Lj. bis einschl. 65.Lj. Report Date: 03-MAR-2016 Report Page: 4 of 4